bevacizumab
Showing 1 - 25 of 1,255
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Bevacizumab
- +2 more
-
Los Angeles, California
- +17 more
Jan 27, 2023
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +5 more
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 13, 2022
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Withdrawn
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Jun 1, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Recruiting
- Hepatocellular Carcinoma
- Candonilimab
- Bevacizumab
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Feb 26, 2023
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,
Recruiting
- Cervical Adenocarcinoma
- +47 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +3 more
Dec 5, 2022
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell
Recruiting
- Locally Advanced Lung Non-Small Cell Carcinoma
- +9 more
- Bevacizumab
- Brigatinib
-
Duarte, California
- +4 more
Aug 17, 2022
Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)
Recruiting
- Colorectal Cancer Metastatic
- Dexamethasone
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Feb 3, 2023
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma
Active, not recruiting
- Fallopian Tube Endometrioid Adenocarcinoma
- +7 more
- Anetumab Ravtansine
- +2 more
-
Orange, California
- +22 more
Oct 22, 2022
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine plus Bevacizumab
- Bevacizumab
-
New Orleans, Louisiana
- +3 more
Dec 16, 2022
Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)
Active, not recruiting
- Invasive Breast Carcinoma
- Triple-Negative Breast Carcinoma
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 18, 2022
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Not yet recruiting
- Metastatic Colon Adenocarcinoma
- +6 more
- Balstilimab
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 17, 2022
Glioblastoma Multiforme, Anaplastic Astrocytoma Trial in New York (Bevacizumab)
Recruiting
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Bevacizumab
-
New York, New YorkLenox Hill Brain Tumor Center
Nov 10, 2022
Glioma Trial in Madison (Bevacizumab, PRDR)
Recruiting
- Glioma
- Bevacizumab
- PRDR
-
Madison, WisconsinUniversity of Wisconsin Hospital and Clinics
Nov 14, 2022
Glioma, Recurrent Glioma Trial in Shanghai (Hypofractionated Stereotactic Radiotherapy, Bevacizumab)
Active, not recruiting
- Glioma
- Recurrent Glioma
- Hypofractionated Stereotactic Radiotherapy
- Bevacizumab
-
Shanghai, Shanghai, ChinaCyberKnife Center, Department of Neurosurgery, Huashan Hospital
Nov 3, 2022
Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer Trial in United States
Recruiting
- Combined Hepatocellular Carcinoma and Cholangiocarcinoma
- +2 more
- Atezolizumab
- +6 more
-
Auburn, California
- +16 more
Aug 17, 2022
Multimodal Deep Learning Radiomic Nomogram for Evaluation of
Not yet recruiting
- Colorectal Cancer
- Liver Metastases
- Bevacizumab
-
Shanghai, Shanghai, ChinaZhongshan hospital
Jan 4, 2023
Solid Tumors Trial run by the National Cancer Institute (NCI) (Bevacizumab, Dasatinib)
Completed
- Solid Tumors
- Bevacizumab
- Dasatinib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 19, 2023
Recurrent Glioblastoma Trial in United States (Bevacizumab, Cediranib, Cediranib Maleate)
Active, not recruiting
- Recurrent Glioblastoma
- Bevacizumab
- +3 more
-
La Jolla, California
- +26 more
Jun 28, 2022
Hepatocellular Carcinoma Trial (Ezurpimtrostat, Atezolizumab, Bevacizumab)
Recruiting
- Hepatocellular Carcinoma
- Ezurpimtrostat
- +2 more
-
Grenoble, FranceUniversity Hospital
Dec 23, 2022
Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- pembrolizumab
- +5 more
-
Hidaka, Saitama, JapanSaitama Medical Uiversity International Medical Center
Apr 25, 2022
Colorectal Cancer Metastatic Trial in Vejle (drug, dietary supplement, other)
Recruiting
- Colorectal Cancer Metastatic
- Fluorouracil
- +6 more
-
Vejle, DenmarkDepartment of Oncology, Vejle Hospital
Nov 17, 2022